Introduction {#Sec1}
============

Tobacco smoking accelerates the process of organ aging and leads to multiple diseases \[[@CR1]--[@CR3]\]. The respiratory system, the frontline attacked by toxic substances in tobacco, often falls victim to diseases such as chronic bronchitis, emphysema, and chronic obstructive pulmonary disease \[[@CR4]\]. Various studies also suggest that smoking can trigger aging-related changes, from cell phenotype to gene expression and epigenetic regulation, in the respiratory system. Fortunately, smoking cessation can effectively reverse these changes \[[@CR5]\]. A photonumeric scale has been developed to confirm that smokers' perioral wrinkles are deeper than non-smokers \[[@CR6]\]. Smoking dysregulates 18 age-related genes and shortened telomere length in small airway epithelia \[[@CR2]\]. Cigarette-smoke exposure induces autophagy impairment, producing aggresome bodies that accelerate lung aging \[[@CR7]\]. Current-smokers, compared to never-smokers, are linked to a 0.74--2.4% decrease of DNA methylation in 11 loci located in lung cancer-related genes \[[@CR8]\]. Smoking cessation relieves respiratory symptoms and bronchial hyperresponsiveness and prevents an excessive decline in lung function \[[@CR9]\]. Peripheral blood epigenetic data are used to confirm that the effects of smoking on DNA methylation are partially reversible 3 months after smoking cessation \[[@CR10]\]. Most of these studies, however, have described the age-related changes qualitatively but not quantitatively, and few have tested the self-healing ability of organs after smoking cessation.

Recent studies have quantified the aging process in the tissue by DNA methylation spectroscopy \[[@CR11]--[@CR13]\], finding that tobacco smoking is associated with epigenetic alterations \[[@CR13], [@CR14]\]. However, most of these epigenetic biomarkers of aging are developed using data from whole blood. Although they can be applied to other tissue samples, the ability of prediction is unstable \[[@CR11], [@CR13]\]. Fortunately, the "epigenetic clock" method, developed by 51 different tissues and cell types, has effectively solved this problem \[[@CR12]\]. Simultaneously, it overcomes the technical obstacles in measuring telomere length in various human systems, including the respiratory system \[[@CR12]\]. At present, the ability of epigenetic clock to predict aging has been verified in studies concerning diet \[[@CR15]\], obesity \[[@CR16]\], lifetime stress \[[@CR17]\], centenarian status \[[@CR18]\], Down syndrome \[[@CR19]\], osteoarthritis \[[@CR20]\], Alzheimer's disease \[[@CR21]\], and Parkinson's disease \[[@CR18]\], but we cannot find analysis on smoking-induced epigenetic age acceleration in the respiratory system.

Here, with the "epigenetic clock" method proposed by Horvath \[[@CR12]\], we evaluated the epigenetic age of buccal cells, airway cells, esophagus, and lung tissue in non-smokers, smokers, and ex-smokers. We quantified the age acceleration by smoking and the aging-inhibiting effect of smoking cessation. The acceleration of epigenetic age may be used to evaluate the detrimental effects of smoking on the respiratory system. Our finding may be encouraging for smokers to cease smoking.

Results {#Sec2}
=======

Epigenetic age of respiratory system measured by DNA methylation {#Sec3}
----------------------------------------------------------------

We found that the DNAm age of non-smokers had a strong linear relationship with the chronological age of the major organs in the respiratory system except the airway cells (Fig. [1](#Fig1){ref-type="fig"}). The null hypothesis of uncorrelation for the airway cells cannot be rejected due to the small sample size (*p* = 0.12, only four data points, Fig. [1](#Fig1){ref-type="fig"}b). We will address the problem of insufficient sample size later in this study. The linear correlation relationship also holds if merging together the smokers and non-smokers (Fig. [1](#Fig1){ref-type="fig"}, black lines). From all the predictions, we found that the DNAm age of airway cells and lung tissue in smokers tended to be greater than that of non-smokers. Fig. 1Correlation between epigenetic age and chronological age. The figure shows scatter plots of epigenetic age (*x*-axis) against chronological age (*y*-axis) in buccal cells (**a**), airway cells (**b**), esophagus tissue (**c**), and lung tissue (**d**). Blue circles, red triangles, and green inverted triangles indicate non-smokers, smokers, and ex-smokers, respectively. The dashed line is the diagonal where epigenetic age equals to chronological age, the blue solid line is the regression of epigenetic age on chronological age for non-smokers, and the black solid line is the regression of epigenetic age on chronological age for all the smokers and non-smokers

Smoking accelerates aging of airway cells and lung tissue {#Sec4}
---------------------------------------------------------

We conducted Kruskal-Wallis tests to verify whether smoking accelerates aging in airway cells and lung tissue, via two measurements on age acceleration developed by Horvath \[[@CR12]\]. The first is AccelerationDiff which equals to DNAm age minus chronological age; the second is AccelerationResidual based on the residual generated by the linear regression (Fig. [1](#Fig1){ref-type="fig"}, the black solid lines) of DNAm age on chronological age \[[@CR12]\]. A positive (negative) value of age acceleration suggests that the organ is older (younger) than its chronological age. In the lung tissue, the AccelerationDiff value of smokers exceeded that of non-smokers by 4.3 years (*p* = 2.7 × 10^−2^, Fig. [2](#Fig2){ref-type="fig"}k). In the airway cells, the AccelerationDiff value of smokers exceeded that of non-smokers by 4.9 years, but the difference was not significant (*p* = 0.45, Fig. [2](#Fig2){ref-type="fig"}e), probably due to the small sample size. In the buccal cells, the AccelerationDiff value of smokers was insignificantly lower than that of non-smokers by 1.64 years (*p* = 0.36, Fig. [2](#Fig2){ref-type="fig"}b). In the esophagus tissues, the AccelerationDiff of smokers was insignificantly higher than that of non-smokers, only by 0.99 years (*p* = 0.97, Fig. [2](#Fig2){ref-type="fig"}h). All the AccelerationResidual values did not show significant differences between smokers and non-smokers (buccal cells, *p* = 0.23; airway cells, *p* = 0.45; esophagus tissues, *p* = 0.18; lung tissue, *p* = 0.25; Fig. [2](#Fig2){ref-type="fig"}c, f, i, and l), but these differences showed trends similar to those in AccelerationDiff value. For example, age acceleration of smokers was faster than that of non-smokers in the airway cells, esophagus tissue, and lung tissue. The difference of chronological age between the two groups was minor in buccal cells, airway cells, and esophagus tissues (buccal cells, *p* = 0.97; airway cells, *p* = 0.24; esophagus tissues, *p* = 0.12; Fig. [2](#Fig2){ref-type="fig"}a, d, and g). In lung tissues, the chronological age of non-smokers was significantly greater than that of smokers (lung tissue, *p* = 2.5 × 10^−2^, Fig. [2](#Fig2){ref-type="fig"}j). Thus, smoking can accelerate the aging of the lung and probably also the airway. Fig. 2Comparison of chronological age and epigenetic age acceleration between smokers and non-smokers. Columns correspond to buccal cells (**a**--**c**), airway cells (**d**--**f**), esophagus tissue (**g**--**i**), and lung tissue (**j**--**l**). Rows correspond to the chronological age (**a**, **d**, **g**, and **j**), AccelerationDiff value (**b**, **e**, **h**, and **k**), and AccelerationResidual value (**c**, **f**, **i**, and **l**). The latter two measure epigenetic age acceleration. The *p* value from Kruskal-Wallis tests is written above each sub-figure

Smoking cessation alleviates epigenetic aging in airway cells but not in lung tissue {#Sec5}
------------------------------------------------------------------------------------

In the airway cells, we found that smoking cessation effectively lowered the rate of aging (ex-smokers vs. smokers, *p* = 5.8 × 10^−4^; Fig. [3](#Fig3){ref-type="fig"}a) down to that of non-smokers (ex-smokers vs. non-smokers: *p* = 0.17, Fig. [3](#Fig3){ref-type="fig"}a). However, in the lung tissues, the accelerated aging rate did not fall significantly after smoking cessation (ex-smokers vs. smokers, *p* = 0.83; ex-smokers vs. non-smokers, *p* = 8.3 × 10^−3^; Fig. [3](#Fig3){ref-type="fig"}b), suggesting that smoking damage to the lung was permanent and irreversible. Fig. 3Change in epigenetic age acceleration after smoking cessation in airway cells, lung tissue and merged (for airway cells) groups. **a**, **b** Comparison of epigenetic age acceleration between non-smokers, smokers, and ex-smokers in airway cells (**a**) and lung tissue (**b**). **c** A scatter plot of epigenetic age (*x*-axis) against chronological age (*y*-axis) in the airway cells (Fig. [1](#Fig1){ref-type="fig"}b). Blue circles indicate now-non-smokers (merge of non-smokers and ex-smokers) and red triangles indicate smokers. The dashed line is the diagonal where epigenetic age equals to chronological age, the blue solid line is the regression of DNAm age on chronological age for now-non-smokers, and the black solid line is the regression of DNAm age on chronological age for all of smokers and now-non-smokers. **d**--**f** The comparison of chronological age (**d**), AccelerationDiff value (**e**), and AccelerationResidual value (**f**) between smokers and now-non-smokers, as updates of Fig. [2](#Fig2){ref-type="fig"}d--f, where ex-smokers were not included in analysis

For the airway cells, the AccelerationDiff value of smokers was larger than that of non-smokers, but the difference was not significant, probably because of the small sample size of non-smokers. Given that there was no significant difference in AccelerationDiff value between ex-smokers and non-smokers, we merged these two groups into a "now-non-smoker" group and re-tested whether smoking accelerated epigenetic aging of airway cells. The results showed that DNAm age of airway cells in now-non-smokers had a strong linear relationship with chronological age (Fig. [3](#Fig3){ref-type="fig"}c). The new comparison showed that in the airway cells, the aging rate of smokers was significantly higher than that of now-non-smokers (*p* = 7.7 × 10^−4^ for AccelerationDiff and *p* = 0.11 for AccelerationResidual, Fig. [3](#Fig3){ref-type="fig"}e, f). Also there was no significant difference in the chronological age between the two groups (*p* = 0.65, Fig. [3](#Fig3){ref-type="fig"}d).

Smoking cessation restores the methylation level of airway cells but not lung tissue {#Sec6}
------------------------------------------------------------------------------------

Based on the 353 CpGs of epigenetic clock, we randomly selected four samples of airway cells and lung tissue from each non-smoker, smoker, and ex-smoker groups (24 samples in total). Firstly, we performed differential methylation analysis on the airway cells and lung tissue of non-smokers and smokers. Fourteen differential methylation sites were screened out in airway cells (*p* \< 0.05) and 34 in the lung tissue (*p* \< 0.01). Subsequently, the above-selected sites were extracted from airway cell samples and lung tissue samples of ex-smokers, and the methylation levels at these sites were observed. We found that the methylation levels of 14 sites in airway cell samples from ex-smokers changed remarkably compared with those of smokers, and tended to return to a level that non-smokers had. However, most sites showed no significant decrease of methylation level in lung tissue samples from ex-smokers (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4DNA methylation levels in non-smokers, smokers, and ex-smokers. The color scales indicate normalized DNA methylation levels, *β* value. The upper part of the heat map shows gene site clusters in airway cell samples, filtered by a methylation level difference (*p* \< 0.05) between sites; the lower part, in lung tissue samples, filtered by a methylation level difference (*p* \< 0.01) between sites. Three sites shared by airway cells and lung tissue are marked with black boxes

By GO analysis, we found that the functions of these sites were enriched in cell senescence and apoptosis, regulation of metabolic processes, tissue development, and Alzheimer's disease. The reduction in methylation level at these sites can be used as an index for smoking-induced accelerated aging.

Gender had no effect on smoking-induced epigenetic age acceleration {#Sec7}
-------------------------------------------------------------------

We found that in the airway cells of both men and women, smoking accelerated the rate of epigenetic aging (*p* = 1.3 × 10^−2^ for males and *p* = 2.0 × 10^−2^ for females, Fig. [5](#Fig5){ref-type="fig"}a, b). But in the lung tissue, only men showed significantly accelerated aging (*p* = 3.5 × 10^−2^ for males and *p* = 0.29 for females, Fig. [5](#Fig5){ref-type="fig"}c, d). To eliminate the bias introduced by the small-size female tissue sample, we used meta-analysis to explore two independent lung tissue datasets of male and female smokers. The meta-analysis suggested that the lung tissue of male smokers did not age faster than that of female smokers (*p* = 0.47, Fig. [5](#Fig5){ref-type="fig"}e). Fig. 5Comparison of epigenetic age acceleration between smokers and non-smokers grouped by gender. Comparison of epigenetic age acceleration of airway cells (**a**, **b**) and lung tissue (**c**, **d**) between smokers and non-smokers, grouped by gender (males, **a** and **c**) and (females, **b** and **d**). **e** A forest plot generated by the meta-analysis on the gender effect on epigenetic age-acceleration of lung tissue in smokers. Each row in the forest plot shows the mean difference in epigenetic age acceleration between males and females in smokers' lung tissue and the 95% confidence interval

Discussion {#Sec8}
==========

Our study quantified the effect of smoking on the aging of respiratory organs based on the "epigenetic clock" method. Our main findings were (1) smoking significantly accelerated the aging of airway cells and lung tissue, but not buccal cells and esophagus tissue; (2) after smoking cessation, the accelerated aging was slowed in the airway cells, but not in the lung tissue; and (3) gender brought no difference in the epigenetic age acceleration in airway cells and lung tissue. We had also tried other estimate methods (developed by Hannum et al. and Levine et al., respectively) \[[@CR11], [@CR13]\]; however, the prediction accuracy was not satisfactory. This is probably because they were developed from whole blood datasets, yet the "epigenetic clock" was developed from the multi-tissue datasets \[[@CR12]\] which was more suitable for this study.

Our study found that the methylation levels in the airway cells and lung tissue changed, a possible reason for altered gene expression detected in previous studies. Differentially expressed genes have been analyzed in small airway epithelia between healthy non-smokers and healthy smokers \[[@CR2]\]. Among them, TRIP10 is a multi-domain adaptor protein whose differential DNA methylation can promote cell survival or cell death in a cell-type-dependent manner \[[@CR22]\]. We found that the methylation level of cg02085507 located upstream of TRIP10 gene was significantly reduced by smoking, corresponding to the upregulation of this gene in Matthew's study \[[@CR2]\]. RPL31 gene associated with cg22809047 is the optimal combination member of ECFCs senescence housekeeping genes \[[@CR23]\]. This site is a differential methylation site in the airway cells and lung tissue, but only the methylation level in airway cells rose to the normal after smoking cessation. In addition, cg15804973 in airway cells is linked to the longevity-associated MAP3K5 gene \[[@CR24]\]. Cg07498421 found in lung tissue is associated with CRADD (also known as RAIDD), an adaptor protein containing a death domain that can oligomerize with PIDD and caspase-2 to initiate apoptosis \[[@CR25]\]. Furthermore, Yafang et al. identified differentially expressed genes between non-smokers and smokers \[[@CR26]\], among which the methylation sites related to CBX7, DKK3, TBX5, SCD5, PTGER2, and BIK genes also showed differential methylation levels in our study. These genes are involved in age-related functions such as cellular senescence \[[@CR27]\], skeletal muscle atrophy \[[@CR28]\], cardiac malformations \[[@CR29]\], brain neurotrophic factors \[[@CR30]\], hair follicle growth \[[@CR31]\], and HSC hematopoietic function \[[@CR32]\]. These studies strongly support our argument that smoking can accelerate the aging of airway cells and lung tissue.

Smoking accelerates the epigenetic age in manners varying among respiratory organs. We surmise that the difference results from the exposure dosage, which is determined by the duration of being exposed to, the surface area contacting to, and the retention capacity of toxins from cigarettes. On the one hand, smoking did not significantly accelerate the aging of buccal cells and esophagus tissue. The buccal cells contact with the toxins transiently though it bears the first brunt. The esophagus tissue is exposed to toxins longer, but with a narrow exposed area. On the other hand, smoking accelerates the aging of airway cells and lung tissue (faster in the later), because the toxins travel a long time through the airway and eventually anchor at the lung.

Smoking cessation at any time can benefit the prevention and treatment of respiratory diseases \[[@CR33]\]. The role of smoking cessation in improving airway and lung function is unquestionable, but its epigenetic mechanism is unclear. We found that after smoking cessation, the methylation level was better reversed in the airway than in the lung, which confirms previous studies on the recovery effect of smoking cessation. For example, the peripheral blood also has the ability of reversible methylation states after smoking cessation \[[@CR10], [@CR13], [@CR34]\].

Conclusion {#Sec9}
==========

We concluded that smoking can accelerate the epigenetic aging of human respiratory organs, but this effect varies among organs and can be reversed by smoking cessation.

Materials and methods {#Sec10}
=====================

DNA methylation datasets {#Sec11}
------------------------

We collated genome-wide methylation datasets of buccal cells, airway cells, esophagus tissue, and lung tissue. These datasets contained records of tobacco exposure (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Briefly, dataset 1 was the epigenome-wide association study based on oral rinse samples from a case-control study of 154 cases and 72 controls \[[@CR35]\]; dataset 2 presented the global methylation data of buccal cells collected from non-smokers, smokers and moist snuff consumers (40 subjects/cohort) \[[@CR36]\]; dataset 3 consisted of small airway cells from 38 ex-smokers: 15 subjects with COPD and 21 with normal lung functio n\[[@CR37]\]; dataset 4 analyzed the genome-wide DNA methylation of airway cells from individuals with and without COPD (non-COPD *n* = 26, COPD *n* = 35) \[[@CR38]\]; dataset 5 evaluated the genome-wide methylation levels in 81 esophageal tissues using HumanMethylation450 Bead Chips (Illumina), including BE, dysplastic BE and EAC epithelial cell s\[[@CR39]\]; dataset 6 covered lung tissues of patients including eight lifelong non-smokers, eight current smokers, and eight patients with COPD \[[@CR40]\]; dataset 7 included tumor and adjacent non-tumor tissues excised from a cohort of 35 patients with stage I lung adenocarcinoma \[[@CR41]\]; dataset 8 contained 24 samples of freshly extracted and frozen tissues from early adenocarcinoma. Smokers/non-smoker group included 6 cases with paired tumor and non-tumor tissue \[[@CR42]\]; dataset 9 included 28 fresh-frozen lung cancer samples, 28 microscopically normal lung tissues, and 6 additional non-tumor control lung tissues. They were all analyzed in parallel by bead array methylation \[[@CR43]\]. All of the datasets were measured on the Illumina 450 K array except two measured on the Illumina 27 K array.

Determination of epigenetic age acceleration {#Sec12}
--------------------------------------------

The normal samples (non-tumor) in the above datasets were selected, and their DNA methylation ages were measured using the epigenetic clock \[[@CR12]\]. The epigenetic clock was defined as an age-predicting method based on the DNA methylation level at 353 CpG sites. We referred to the predicted age as the DNAm age. The universal measure of age acceleration (AccelerationDiff) was defined as the difference between the DNAm age and the chronological age; another measure of acceleration (AccelerationResidual) equaled the residual resulting from linear regressing DNAm age on chronological age (Fig. [1](#Fig1){ref-type="fig"}, black lines). Epigenetic clock procedures were performed according to the instructions on the website (<https://dnamage.genetics.ucla.edu>) \[[@CR12]\].

Statistical analysis between groups {#Sec13}
-----------------------------------

The Kruskal-Wallis test was applied to determine the significant difference between the two groups (non-smokers/smokers or non-smokers/ex-smokers or ex-smokers/smokers). The effect of gender in smokers on the methylation age of lung tissue was determined by meta-analysis. *p* values of less than 0.05 were considered to be significant. Statistical analysis was performed using R Studio. The meta-analysis was implemented in the *metafor* R package; the forest plot was drawn by the *forestplot* R package.

Differential methylation analysis between three smoking states {#Sec14}
--------------------------------------------------------------

The differences in methylation levels at 353 age-related methylation loci between non-smokers and smokers groups were examined using the *limma* package in R Studio. The *heatmap* was drawn by the *pheatmap* R package.

Supplementary information
=========================

 {#Sec15}

**Additional file 1: Table S1.** Summary of the DNA methylation datasets.

DNA

:   Deoxyribonucleic acid

GO

:   Gene Ontology

ECFCs

:   Endothelial colony forming cells

CRADD (RAIDD)

:   CASP2 and RIPK1 domain containing adaptor with death domain

PIDD

:   p53-induced death domain protein 1

HSC

:   Hematopoietic stem cell

COPD

:   Chronic obstructive pulmonary disease

BE

:   Barrett's esophagus

EAC

:   Esophageal adenocarcinoma

GEO

:   Gene Expression Omnibus
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